Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio— have products in the pipeline that could ...

Mucopolysaccharidosis Type II (MPS II) also known as Hunter Syndrome is when the body lacks the enzyme to break down sugar molecules in the body and remove them.

Cushing's syndrome is fairly rare. It most often affects adults who are 20 to 50 years old. It is sometimes called hypercortisolism. You will probably need to see a specialist in hormone-related ...

When is the next Monster Hunter Wilds beta? The previous Monster Hunter Wilds open beta included a limited portion of the game for players to test, including spending time in the character creator ...

Hunter was born on October 15, 1978, in Yorkshire. He was a keen snooker player from a young age and made his professional debut in July 1995 when he was just 16 years old. Paul won the Masters ...

What are the Monster Hunter Wilds monsters? The best way for any hunter to prepare for a trip to the Forbidden Lands is to get familiar with all the monsters that call it home. Capcom has already ...

Fifteen-year-old Dominic Henriquez from Prosper, Texas, is bringing hope to boys like him who live with Hunter syndrome, a rare genetic disorder that primarily affects males. Dominic’s journey ...

Nip­pon Shinyaku has paid $110 mil­lion up­front for the rights to sell two of Re­genxbio’s gene ther­a­pies for mu­copolysac­cha­ri­do­sis in the US and Asia. … ...

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now found a commercialization partner for both the U.S. and Asian markets.

The partnership will focus on advancing RGX-121 as a treatment for mucopolysaccharidosis II (MPS II), also known as Hunter syndrome, and RGX-111 for treating mucopolysaccharidosis I (MPS I), also ...